Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain

BOSTON and ATHENS, Ga., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the U.S. Patent and Trademark Office has allowed U.S. Patent Application No. 17/238760, entitled Neural Cell Extracellular Vesicles, with method of use claims pertaining to its lead program, AB126, for the treatment of neuro-inflammatory diseases. AB126 is an exosome derived from proprietary neural stem cells and has been shown to reduce inflammation in the brain.